Chinese scientists turn tumours into ‘pork' in radical cancer treatment
cancer
Advertisement
In a trailblazing fusion of immunology and ingenuity, a team of Chinese researchers have been engineering tumours to mimic pork, thereby triggering the body's
immune system to attack them with unprecedented precision.
Their pioneering study, published in the journal Cell on January 18, uses a genetically modified virus to 'disguise' cancer cells as foreign pig tissue, sparking a hyperacute immune rejection response that attacks the tumours while leaving healthy cells untouched.
Early clinical trials report staggering success: 90 per cent of patients with advanced, treatment-resistant cancers – such as liver, ovarian and lung – achieved halted tumour growth or shrinkage, with one cervical cancer patient declared clinically cured.
By repurposing a mechanism that is notorious for
organ transplant rejection, this 'tumour-to-pork' strategy has opened a new frontier in the fight against cancer, offering hope where conventional therapies have failed.
Advertisement
The study, led by Professor Zhao Yongxiang, director of the State Key Laboratory of Targeting Oncology, Guangxi Medical University, is now trending on China's social media.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
2 hours ago
- South China Morning Post
Pfizer, Chinese biotech firm 3SBio complete worldwide licensing deal for cancer drug
First announced in May, the deal will see 3SBio – based in Shenyang, capital of northeastern Liaoning province – receive a US$1.25 billion upfront payment from Pfizer for the exclusive right to sell its cancer drug, SSGJ-707, outside China. Under the terms of their agreement, Pfizer will also pay 3SBio up to US$150 million to solely develop and commercialise SSGJ-707 within the mainland, the two companies said on Thursday. Pfizer also agreed to buy 31.1 million new shares in S3Bio, or a 1.3 per cent equity stake, for HK$785 million, according to a stock exchange filing. The deal at HK$25.2055 per share represents a 17 per cent discount to its market price on Thursday. 3SBio's shares fell 6.41 per cent to HK$28.45 on Friday. The transaction reflected the strong momentum of Chinese biotech firms in the field of drugs research and the increased interest from major foreign pharmaceutical companies to license their intellectual property.
HKFP
3 hours ago
- HKFP
Amazon shuts down AI lab in Shanghai, source says
US tech giant Amazon has shut down its artificial intelligence research lab in Shanghai, a source with direct knowledge of the matter confirmed to AFP. News that the lab, part of cloud division Amazon Web Services (AWS), has closed comes with AI at the forefront of a tech race between China and the United States. In a screenshot of a WeChat post widely circulated on Chinese social media this week, Wang Minjie, a scientist at the lab, said its disbanding was 'due to the strategic adjustment between China and the United States'. AWS announced job cuts across its operations last week, with some reports putting the losses at hundreds. Amazon declined to confirm the Shanghai lab's closure directly when contacted by AFP. 'We've made the difficult business decision to eliminate some roles across particular teams in AWS,' spokesman Brad Glasser said in a similar statement to the one released in response to the broader job losses. 'These decisions are necessary as we continue to invest, hire, and optimize resources to deliver innovation for our customers.' A dedicated AWS China webpage for the lab seen on Wednesday by AFP was no longer accessible on Friday. According to an archive of the page, the lab was established in autumn 2018, with part of its remit to 'actively foster collaboration with the research community'. Other US tech firms such as Microsoft and IBM have scaled back their research divisions in China recently, as the tech competition between Washington and Beijing shows no sign of abating.
South China Morning Post
13 hours ago
- South China Morning Post
China unveils the largest crystal for high-powered laser weapons
Chinese researchers have manufactured the world's largest barium gallium selenide (BGSe) crystal, a breakthrough that could pave the way for ultra-high-power laser weapons capable of zapping satellites from the ground. The synthetic crystal, measuring 60 millimetres (2.3 inches) in diameter, efficiently converts short-wave infrared lasers into mid- to far-infrared beams that can penetrate atmospheric windows for long-distance transmission. Crucially, it can withstand laser power as intense as 550 megawatts per square centimetre – exceeding the damage threshold of existing military-grade crystals by an order of magnitude. The resulting laser frequency converter – measuring 10×10×50 mm (0.4x0.4x2 inches) – dwarfs conventional optics, typically limited to tiny and thin components. 'This represents the largest specimen reported globally to date,' wrote the research team led by Professor Wu Haixin in a peer-reviewed paper published in June by the Chinese-language Journal of Synthetic Crystals. For decades, self-damage in laser weapons has crippled their power and range. The US Navy's 1997 MIRACL mid-infrared laser test, which accidentally melted its own components while targeting a satellite, underscored the challenge.
